Evaluation of clinical outcomes of COVID-19 in patients taking remdesivir in complex therapy in routine clinical practice
Remdesivir (GS-5734) is a new direct-acting antiviral drug in the nucleotide analogue class with antiviral activity against SARS-CoV-2 and the ability to inhibit RNA-dependent RNA polymerase. Preliminary results from phase III randomized clinical trials of remdesivir are inconsistent. Understanding the fact of the limited world experience with the use of remdesivir in COVID-19 required further study of its efficacy and safety in real clinical practice.
The aim of the study is to evaluate the efficacy and safety of remdesivir in the treatment of patients with COVID-19.
Material and methods. The study included 1422 patients with a novel coronavirus infection (COVID-19) who received remdesivir as part of complex therapy in a hospital setting at medical organizations of the Moscow public health system.
Additionally, standard therapy was carried out, regulated by the Interim Guidelines “Prevention, Diagnosis and Treatment of Novel Coronavirus Infection (COVID-19)” of the Ministry of Healthcare of the Russian Federation, the current version.
The efficacy of the drug was assessed based on primary and secondary efficacy points. Primary variable: 1) cumulative incidence of clinical outcomes in patients with COVID-19 treated with remdesivir as part of complex therapy; 2) median time to clinical improvement according to the World Health Organization ordinal categorical scale (under clinical improvement, the patient is assumed to move >2 categories towards improvement in clinical condition). Secondary variables: 1) median time to achieve <2 NEWS scores lasting at least 24 hours or hospital discharge; 2) mortality from all causes; 3) duration of fever (>38 °C), days; 4) duration of hospitalization, days; 5) time to achieve elimination of the pathogen from the upper respiratory tract (no SARS-CoV-2 RNA), days.
The safety of remdesivir was assessed based on the registration of adverse events using the method of spontaneous reports.
Results. The analysis of clinical outcomes of treatment showed that 1195 (84.1%) patients recovered, death from all causes occurred in 227 (15.9%) patients. The median improvement in clinical status on the World Health Organization ordinal categorical scale was 6 days. The median time to reach a NEWS score of <2, lasting at least 24 hours, or hospital discharge was 4 days. The median duration of fever was 3 days from the start of remdesivir administration. The median length of hospital stays for patients included in the Register was 9 days. Adverse reactions associated with the use of remdesivir were recorded in 11 (0.7%) patients. Serious adverse reactions were not registered. During hospitalization, all adverse reactions were resolved.
Conclusion. A retrospective analysis of data from the Registry of 1422 patients with COVID-19 who received remdesivir as part of complex therapy in medical organizations of the state healthcare system of Moscow in routine clinical practice showed clinical efficacy and a favorable safety profile of remdesivir (Remdeform®, lyophilizate for solution for intravenous administration 100 mg, manufactured by JSC Pharmasyntez, Russia). The data obtained are consistent with previous randomized clinical trials of remdesivir and allow us to recommend its further use in patients with COVID-19 as part of complex therapy.
Keywords:СOVID-19; coronavirus disease; SARS-CoV-2; remdesivir
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Zhuravleva M.V., Kuznetsova E.V., Kameneva T.R., Kulikov A.N., Laryushkina E.D., Romashov O.M., Andreev S.S., Ivzhits M.A., Zernova E.V., Mitrokhin S.D., Bikbaeva T.V., Filatova A.P., Kryukov A.V., Khokhlov A.A., Abusev I.D. Evaluation of clinical outcomes of COVID-19 in patients taking remdesivir in complex therapy in routine clinical practice. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (2): 38–48. DOI: https://doi.org/10.33029/2305-3496-2022-11-2-38-48
1. Lo M.K., Jordan R., Arvey A., et al. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep. 2017; 7: 43395. DOI: https://doi.org/10.1038/srep43395
2. Sheahan T.P., Sims A.C., Graham R.L., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9: eaal3653. DOI: https://doi.org/10.1126/scitranslmed.aal3653
3. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9 (2): e00221-18. DOI: https://doi.org/10.1128/mBio.00221-18
4. Summary on compassionate use remdesivir Gilead. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf (Accessed May 5, 2020).
5. Grein J., Ohmagari N., Shin D., et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; published online April 10. DOI: https://doi.org/10.1056/NEJMoa2007016
6. Wang Y., Zhang D., Du G., Du R., et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395 (10236): 1569–78. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9
7. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020; 383; (19): 1813–26. DOI: https://doi.org/10.1056/NEJMoa2007764
8. Spinner C.D., Gottlieb R.L., Criner G.J., Arribas López J.R., et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324 (11): 1048–57. DOI: https://doi.org/10.1001/jama.2020.16349
9. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2021; 384 (6): 497–511. DOI: https://doi.org/10.1056/NEJMoa202318
10. Kalil A.C., Patterson T.F., Mehta A.K., Tomashek K.M., et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021; 384: 795–807. DOI: https://doi.org/10.1056/NEJMoa2031994
11. Gottlieb R.L., Vaca C.E., Paredes R., Mera J., et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients // N Engl J Med. 2022; 386: 305–15. DOI: https://doi.org/10.1056/NEJMoa2116846
12. Mirzaev K.B., Tsvetov V.M. Scientific rationale for the use of remdesivir in patients with COVID-19. Pharmateca [Farmateka]. 2020; (13): 17–20. DOI: https://dx.doi.org/10.18565/pharmateca.2020.13.17-20 (in Russian)
13. The COVID-19 Treatment Guidelines Panel’s Statement on Therapies for High-Risk, Nonhospitalized Patients with Mild to Moderate COVID-19. NIH: COVID-19 Trearment Gudelines. Last Update: January, 19, 2022.
14. Remdeform (Remdesivir). Instructions for medical use of the drug (ЛП-006505 of October 14, 2020). (in Russian)
15. Temporary guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). 9th ed. Moscow, 2020: 235 p. (in Russian)
16. Goldina T.A., Kolbin A.S., Belousov D.Yu., Borovskaya V.G. Review of real-world data study. Kachestvennaya klinicheskaya praktika [Good Clinical Practice]. 2021; (1): 56–63. DOI: https://doi.org/10.37489/2588-0519-2021-1-56-63 (in Russian)